Ursodeoxycholic acid - Retrophin

Drug Profile

Ursodeoxycholic acid - Retrophin

Alternative Names: L-UDCA; liquid formulation ursodeoxycholic acid; ursodeoxycholic acid liquid

Latest Information Update: 29 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asklepion Pharmaceuticals
  • Developer Retrophin
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants
  • Mechanism of Action Apoptosis inhibitors; Cholesterol inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Primary biliary cirrhosis

Most Recent Events

  • 20 Jun 2016 Retrophin acquires ursodeoxycholic acid (liquid formulation) from Asklepion Pharmaceuticals
  • 20 Jun 2016 Retrophin announces intention to submit NDA to US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top